GSK_Annual_Report_2021

Annual Report 2020-21 37 to prudently adopt all necessary personal safety and physical distancing guidelines to resume field work. In line with the changing business realities, your Company adapted its in-clinic communication to the need for delivery of key messages with greater immediacy and impact. These initiatives led to gains in the market share for your Company across the categories of Anti- Infectives, Pain, Dermatology, Vitamins, Minerals and Supplements. The Evolution Index for top brands stood at: Augmentin 119 , Ceftum 112 , Calpol 103 , T-Bact 104 , Cobadex CZS 117 (IMS MAT March 2021). Your Company also continued to focus on effective partnerships with key healthcare organisations to engage on important topics, such as judicious use of antibiotics, particularly after the administration of COVID-19 vaccine. Besides leading the topical antibiotics market, your Company has been making gains consistently in the topical corticosteroids and emollient categories. Even though Dermatology was one of the adversely impacted segments, your Company maintained and consolidated its leadership in this segment during the year by remaining digitally engaged with key opinion leaders. Virtual platforms, such as Tell e-Skin, were deployed during the lockdown to disseminate the opinions and information shared by dermatology experts with general practitioners and pediatricians on diagnosis and use of steroids, thereby improving the outcome for patients. Biologicals Five of your Company’s vaccines feature among the top 20 vaccines in the self-pay market (IMS MAT March 2021), in which it remains the No. 1 company. Though the vaccines self-pay market is estimated to be over ` 2,500 crores, it is currently not reflecting any value growth (IMS MAT March 2021) on account of the slower uptake of vaccination during the COVID-19 related lockdowns. Your Company currently markets 10 vaccines across age groups - infants, adolescents and adults. In September 2020, it launched tetravalent influenza Northern Hemisphere vaccine ( Fluarix Tetra NH 2020-21) to help combat influenza. Within three months of the launch, the vaccine had garnered 30% volume share in the market. The vaccine, which builds on the demonstrated promise of Menveo that was launched in 2019, is a testament to the Company’s strategy of leveraging the global innovation pipeline while bringing differentiated, high-quality vaccines to addressable markets. Your Company launched three engaging direct- to-consumer awareness campaigns during the year to strengthen its value proposition in this segment. It has also partnered with the Federation of Obstetric and Gynaecological Societies of India (FOGSI) and Indian Academy of Pediatrics (IAP) to increase awareness about vaccination and the benefits of its vaccines. Your Company plans to continue to grow its vaccines business by launching new brands to optimise its portfolio and by expanding into new consumer segments. Supply chain Manufacturing excellence Consistent with your Company’s pursuit of excellence, the Nashik manufacturing facility is positioned to be critical to supply chain and sourcing. The facility continued to invest in culture improvement initiatives, while ensuring unhindered supply of products to patients. During the year, the Nashik manufacturing facility set new benchmarks in excellence: • Over three million safe person hours without reportable illnesses; • 81% reduction in repeat deviations (from 14.9% to 2.8%); • Significant improvement in productivity Warehousing and distribution The COVID-19 crisis necessitated agile adaptation of the supply chain operations, in keeping with the prevailing government mandates. Your Company conformed to the regulations notified by the government from time to time, by coordinating with more than 30 manufacturing facilities, 26 warehouses, 6,000 stockists, a distribution team of more than 700 external workers across warehousing and 280 transporters across the country. Your Company is pleased to report that there was not a single day of interruption or delay in the supply chain network during the year.